Dechra Pharmaceuticals (LON:DPH) Shares Pass Above 200-Day Moving Average of $3,386.14

Dechra Pharmaceuticals PLC (LON:DPHGet Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 3,386.14 ($42.68) and traded as high as GBX 3,813.71 ($48.07). Dechra Pharmaceuticals shares last traded at GBX 3,810 ($48.03), with a volume of 302,148 shares.

Analysts Set New Price Targets

A number of equities analysts have recently commented on DPH shares. Numis Securities restated a “buy” rating and set a GBX 4,000 ($50.42) price objective on shares of Dechra Pharmaceuticals in a research note on Monday, May 22nd. Deutsche Bank Aktiengesellschaft restated an “outperform” rating and set a GBX 4,070 ($51.30) price objective on shares of Dechra Pharmaceuticals in a research note on Thursday, May 25th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from, Dechra Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of GBX 3,672 ($46.29).

View Our Latest Report on DPH

Dechra Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 60.73, a quick ratio of 1.66 and a current ratio of 2.73. The stock’s fifty day moving average price is GBX 3,733.51 and its 200-day moving average price is GBX 3,386.14. The company has a market capitalization of £4.34 billion, a P/E ratio of 10,583.33, a PEG ratio of 1.42 and a beta of 0.80.

About Dechra Pharmaceuticals

(Get Free Report)

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.

See Also

Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with's FREE daily email newsletter.